StockData

Allarity Therapeutics vs Scienture

ALLR and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALLR and SCNX compare

Scienture is the larger company, worth 8.8 times as much as Allarity Therapeutics ($123M against $13.9M).

Scienture scores higher on the StockData Score (3 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALLRSCNX
Size and price
Market cap$13.9M$123M
Share price$0.875$2.99
Change, 1 year−26.5%−82.2%
Change, 5 years–−99.8%
Beta (5Y)1.411.07
Employees88
StockData Score
Total score13 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/B3.9×1.9× (better)
Growth
Revenue growth, 5Y average–−52.1%
Profitability
Return on equity−157%−53.5% (better)
Return on invested capital−957%−47.3% (better)
Financial health
Debt / equity5.90–
Interest coverage−10.1× (better)−13.1×
Current ratio1.113.04 (better)
Altman Z-score−6.640.31 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield6.4%–
Shareholder yield6.4% (better)0.00%
Ownership
Held by institutions8.1%–
Held by insiders6.3%16.6%
Short interest, % of float1.5%0.34%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.